1. Home
  2. BAC vs GILD Comparison

BAC vs GILD Comparison

Compare BAC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank of America Corporation

BAC

Bank of America Corporation

HOLD

Current Price

$57.52

Market Cap

380.6B

Sector

Finance

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$125.74

Market Cap

168.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAC
GILD
Founded
1784
1987
Country
United States
United States
Employees
213000
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
380.6B
168.6B
IPO Year
N/A
2003

Fundamental Metrics

Financial Performance
Metric
BAC
GILD
Price
$57.52
$125.74
Analyst Decision
Buy
Strong Buy
Analyst Count
20
18
Target Price
$60.34
$148.39
AVG Volume (30 Days)
36.0M
7.6M
Earning Date
04-15-2026
05-07-2026
Dividend Yield
2.12%
2.55%
EPS Growth
N/A
1684.21
EPS
N/A
1.61
Revenue
N/A
$24,689,000,000.00
Revenue This Year
$13.11
$4.68
Revenue Next Year
$5.80
$6.04
P/E Ratio
$14.01
$77.67
Revenue Growth
N/A
9.98
52 Week Low
$44.75
$107.75
52 Week High
$58.01
$157.29

Technical Indicators

Market Signals
Indicator
BAC
GILD
Relative Strength Index (RSI) 70.63 43.66
Support Level $51.20 $116.55
Resistance Level N/A $126.46
Average True Range (ATR) 1.09 3.48
MACD 0.31 0.06
Stochastic Oscillator 85.80 40.31

Price Performance

Historical Comparison
BAC
GILD

About BAC Bank of America Corporation

Bank of America is a formidable financial titan with a $3.5 trillion balance sheet and a cornerstone of the American economy, holding the second-largest deposit market share in the United States. While the firm has maintained its stronghold among middle-market and retail clientele domestically, Bank of America has continued to hold its own on the global stage, as evidenced by its fourth-largest global trading operation and an investment banking division that regularly finishes in the top four in global league tables. The firm is organized across four segments: consumer banking, global wealth and investment management, global banking, and global markets.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: